close to the cut-off (41 -49 mmol/mol) will be retested in 6-12 months and will enter a lifestyle programme where cardiovascular risk factors will be appropriately addressed. Although they will not acquire the diagnostic label of diabetes, nor enter an annual programme of microvascular complications screening at that time, they are not really being 'missed'. In addition, although glucose-based criteria remain valid, the NZSSD recommendations strongly favour HbA 1c as the diagnostic test in preference to oral glucose tolerance testing (OGTT) and as a consequence, New Zealand has witnessed a significant increase in HbA 1c testing and corresponding decline in OGTT requests. Furthermore, as Andrew Day 1 also highlights, glucose-based criteria remain preferable wherever there may be abnormal red cell turnover or haemoglobinopathy.
Evaluation of haemolysis in emergency department samples requesting high sensitivity troponin T measurement
There have been several recent reports in Annals of Clinical Biochemistry concerning a new and highly sensitive troponin T (hsTnT) assay. One study compared the hsTnT assay to conventional troponin assays for the early detection of myocardial infarction in an emergency department. 1 This study demonstrated better performance of the hsTnT assay compared with the fourth-generation TnT assay and that diagnostic accuracy was improved when a follow-up sample was tested. In a second report, analytical evaluation of the hsTnT assay showed that haemolysis impacts the assay results with haemoglobin concentrations above 0.25 g/dL, reducing troponin T concentrations by 20%. 2 These results confirmed previous studies by Bais 3 and Florkowski et al., 4 who showed that negative interference could be as high as 60% in heavily haemolysed samples. Moreover, the assay manufacturer (Roche Diagnostics, Mannheim, Germany) claims that haemoglobin concentrations above 0.1 g/dL may cause interference and loss of assay precision.
Having used the hsTnT assay for several months in our laboratory, we sought to determine the extent to which results might be affected by haemolysis in our emergency department. To accomplish this, we evaluated the frequency of haemolysed blood samples in our emergency department and classified them according to their haemolysis index (HI; measured by spectrophotometry), which corresponds to 0.05, 0.1, 0.25, 0.5 and 1 g/dL of haemoglobin. We measured hsTnT using electrochemiluminescence on Cobas 8000 (e602) analysers and systematically incorporated the HI into the assay result. The HI correlated well with haemoglobin concentration (Figure 1) . During a three-month period, hsTnT was measured in approximately 2500 samples from the emergency department. Haemolysed samples were frequently encountered, with more than 15% of samples having substantial haemolysis (HI above 50, the level at which the plasma potassium concentration is significantly affected). A similarly high frequency has been also reported by Berg et al., 5 who found a frequency of haemolysed samples of 10.7% with an index cut-off above 70. Using this cut-off, we observed the same frequency (10.9%). According to the hsTnT manufacturer's recommendations, haemolysis would impact up to 7% of our emergency department samples. However, this more conservative haemoglobin concentration limit of 0.1 g/dL causes troponin T concentrations to decrease by only 5 -10%. Using a haemoglobin limit of 0.25 g/dL taken from 
Effect of Patent Blue V w dye on sample interference indices on the Abbott Architect
We read with interest an article on the interference caused by Patent Blue V w dye in the serum sample interference indices on the Roche modular (F Hoffmann-La Roche, Basel, Switzerland), 1 after noticing the same dye caused a similar effect on these indices on the Abbott Architect (Abbott Laboratories, Chicago, IL, USA). Patent Blue V w is a dye that is used in certain surgical procedures, in particular to guide sentinel lymph node biopsy. 2 Its use carries the potentially fatal side-effect of anaphylatic reaction. 3, 4 The dye has also been shown to cause interference in pulse oximetry and co-oximetry. 5 We noticed that administration of Patent Blue V w dye for a surgical procedure caused a patient's serum sample to take on a green appearance, which was most apparent in the sample taken immediately postsurgery. The green colour was still present, but less intense, in a sample taken five hours after surgery, but had returned to a normal yellow appearance in a sample taken the following day (20 h postsurgery).
We found negative changes in the haemolysis and icterus indices on the Abbott Architect in the green samples, which correlated with the intensity of the colour (Figure 1 ). In addition, the dye caused positive interference in the lipaemia index. These findings are consistent with those of the study on the effect of Patent Blue V w on the Roche modular sample interference indices. 1 Scanning spectrophotometry (between 326 and 700 nm) using a Unicam UV/visible spectrophotometer (Unicam Analytical Systems, Madison, WI, USA) revealed a peak at 630 nm in the green samples (Figure 1) , which was not present in the serum sample with a normal appearance. The presence and size of the peak at 630 nm correlated with the change in the sample interference indices. In addition, there was a peak at 413 nm in all samples, which was largest in the sample with a normal appearance.
Sample interference indices for haemolysis, lipaemia and icterus on the Abbott Architect are calculated using specific formulae following bichromatic spectrophotometric readings at 500/524 nm (A1), 572/604 nm (A2), 628/660 nm (A3) and 524/804 nm (A4). The peak at 630 nm in the green samples would be expected to affect at least the A2 and A3 readings, thus explaining the effect on the interference indices.
The dye did not appear to affect routine biochemical measurements (data not shown), consistent with the findings of the study on the Roche modular. 1 However, the interference caused by Patent Blue V w has the potential to mask the presence of haemolysis or icterus, and exaggerate the presence of lipaemia. Therefore, in theory, a spurious result could be issued in such samples, e.g. a falsely elevated potassium concentration. We recommend interpreting biochemical results with caution in serum samples affected by Patent Blue V w and considering possible hidden haemolysis or icterus when these indices are apparently 'normal'.
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